Trial Profile
Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 26 Jul 2019 Status changed from recruiting to withdrawn prior to enrolment as the study was on hold for protocol redesign; decided to not move forward with study
- 15 Jan 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 02 Jan 2018 Planned number of patients changed from 10 to 100.